ConSynance Therapeutics Receives FDA Rare Pediatric Disease Designation for CSTI-500 in Prader-Willi Syndrome
ConSynance Therapeutics receives FDA Rare Pediatric Disease Designation for CSTI-500 in Prader-Willi Syndrome, aiming to address hyperphagia and severe temper outbursts through a Triple Monoamine Reuptake Inhibitor.
Highlighted Terms
Related News
ConSynance Therapeutics Receives FDA Rare Pediatric Disease Designation for CSTI-500 in Prader-Willi Syndrome
ConSynance Therapeutics receives FDA Rare Pediatric Disease Designation for CSTI-500 in Prader-Willi Syndrome, aiming to address hyperphagia and severe temper outbursts through a Triple Monoamine Reuptake Inhibitor.